For the quarter ended December 2023, Boston Scientific (BSX) reported revenue of $3.73 billion, up 14.9% over the same period last year. EPS came in at $0.55, compared to $0.45 in the year-ago quarter. The reported revenue represents a surprise of +3.77% over the Zacks Consensus Estimate of $3.59 billion. With the consensus EPS estimate being $0.51, the EPS surprise was +7.84%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Boston Scientific Corp.’s stock BSX, +0.18% jumped 5.8% early Wednesday, after it beat estimates for the fourth quarter and offered upbeat guidance for 2024. The Marlborough, Mass.-based medical technology company posted net income of $504 million, or 34 cents a share, for the quarter, up from $126 million, or 9 cents a share, in the year-earlier period. Excluding special items, the company had EPS of 55 cents, ahead of the 51 cent FactSet consensus. Sales rose 14.9% to $3.725 billion, well ahead of the $3. ...

MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago a ...

波士顿科学盈利预测 - 华尔街分析师预测波士顿科学（BSX）将在下一份报告中每股盈利为0.51美元，同比增长13.3%[1] - 分析师对波士顿科学的季度盈利预测在过去30天内上调了0.2%[2] - 在公司发布财报之前，重要考虑对盈利预测的任何修订，这些修订对预测投资者对股票行为的潜在影响至关重要[3] - 分析师的综合评估显示，波士顿科学特定关键指标的平均预测值[4]

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis ...

Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2023 results on Jan 31, before the opening bell. In the last reported quarter, the company’s earnings per share of 50 cents exceeded the Zacks Consensus Estimate by 4.2%. BSX’s bottom line beat estimates in three of the trailing four quarters and missed on one occasion. The company has a trailing four-quarter earnings surprise of 4.34% on average. Factors at Play With U.S. hospitals reporting an increase in the number of ...

医疗科技股2024年展望 - 预计医疗科技股将在2024年跑赢大盘[1] - 爱尔康、史赛克、库珀医疗、Axonics和波士顿科学是Baird对2024年医疗科技股的首选[3] - 医疗技术患者数量在第四季度保持良好，需求强劲，公司超过了华尔街对第四季度收入的预期[4]

强生（Johnson & Johnson）收购Ambrx - 强生将斥资20亿美元收购Ambrx，展示了其实验性抗体药物结合物（ADCs）的有望测试结果[1][4] 默克（Merck）收购Harpoon Therapeutics - 默克承诺支付6.8亿美元收购Harpoon Therapeutics，该公司在肿瘤学领域有重要进展[1][4] 波士顿科学（Boston Scientific）收购Axonics - 波士顿科学花费37亿美元收购Axonics，该公司生产神经调节工具，帮助患有膀胱过度活动和大便失禁的患者[1][5] 上市公司股价表现 - AMAM股价在盘前交易中飙升99%，HARP股价飙升近111%，AXNX股价也上涨20%[6]

Shares of Axonics Inc. AXNX, -0.84% soared 19.2% toward a 13-month high in premarket trading Monday, after the medical technology company focused on treating urinary and bowel dysfunction announced an agreement to be acquired by Boston Scientific Corp. BSX, -0.02% in a cash deal with an equity value of about $3.7 billion. Under terms of deal, Boston Scientific will pay $71 for each Axonics shares outstanding, which represents a 23.3% premium to Friday’s closing price of $57.57. Boston Scientific’s stock tac ...

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass., Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per s ...